Dresden Germany 30 September, 2014 — LimFlow today announced that it has closed its Series A financing with a major Family Fund leading the round. The terms and amount were not discussed.
About LimFlow GmbH
LimFlow is a private, venture-backed medical device company offering a novel therapeutic to treating Critical Limb Ischemia. LimFlow is enrolling patients into its feasibility clinical study using its patented Percutaneous Deep Vein Arterialization in Singapore and Leipzig Germany with its CE Mark trial to being in early 2015.
For more information about LimFlow, please visit www.LimFlow.com. The LimFlow System is not approved for sale in Europe and is not approved for sale or investigational use in the United States. For additional information, contact Tim Lenihan, CEO, LimFlow GmbH ; email@example.com or +49 173 356 8405.